[go: up one dir, main page]

AR120914A1 - PROTEÍNAS DE UNIÓN A TGF-b-RII - Google Patents

PROTEÍNAS DE UNIÓN A TGF-b-RII

Info

Publication number
AR120914A1
AR120914A1 ARP200103661A ARP200103661A AR120914A1 AR 120914 A1 AR120914 A1 AR 120914A1 AR P200103661 A ARP200103661 A AR P200103661A AR P200103661 A ARP200103661 A AR P200103661A AR 120914 A1 AR120914 A1 AR 120914A1
Authority
AR
Argentina
Prior art keywords
antibody
tgf
antibody fragment
binding proteins
present
Prior art date
Application number
ARP200103661A
Other languages
English (en)
Inventor
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of AR120914A1 publication Critical patent/AR120914A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C07K16/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un anticuerpo o fragmento de anticuerpo del mismo que específicamente se une al dominio extracelular de TGF-bRII humano. La presente además se refiere a un vector que comprende un polinucleótido que codifica el anticuerpo o fragmento de anticuerpo de la presente, una célula aislada que produce el anticuerpo o fragmento de anticuerpo de la misma, y una composición farmacéutica que comprende el anticuerpo o fragmento de anticuerpo de la misma. En anticuerpo o fragmento de anticuerpo de la presente se puede usar para tratar cáncer.
ARP200103661A 2019-12-24 2020-12-23 PROTEÍNAS DE UNIÓN A TGF-b-RII AR120914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24

Publications (1)

Publication Number Publication Date
AR120914A1 true AR120914A1 (es) 2022-03-30

Family

ID=69700252

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200103661A AR120914A1 (es) 2019-12-24 2020-12-23 PROTEÍNAS DE UNIÓN A TGF-b-RII
ARP230102989A AR130991A2 (es) 2019-12-24 2023-11-07 PROTEÍNAS DE UNIÓN A TGF-b-RII

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230102989A AR130991A2 (es) 2019-12-24 2023-11-07 PROTEÍNAS DE UNIÓN A TGF-b-RII

Country Status (14)

Country Link
US (1) US20250270331A1 (es)
EP (2) EP4269433A3 (es)
JP (3) JP7633259B2 (es)
KR (2) KR20230145542A (es)
CN (3) CN116199780A (es)
AR (2) AR120914A1 (es)
AU (2) AU2020412201A1 (es)
BR (1) BR112022012522A2 (es)
CA (1) CA3165605A1 (es)
IL (2) IL294181A (es)
MX (2) MX2022007919A (es)
PH (1) PH12022551527A1 (es)
TW (2) TW202417513A (es)
WO (1) WO2021133167A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7633259B2 (ja) * 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質
WO2023089083A1 (en) * 2021-11-19 2023-05-25 Merus N.V. Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
EP4638501A1 (en) 2022-12-20 2025-10-29 Merus N.V. Fap binding domains and bispecific binding moieties that bind fap and tgf-beta rii

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
CA2729095C (en) 2008-06-27 2018-12-04 Merus B.V. Method for producing a transgenic murine mammal
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CN103443126B (zh) * 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
AU2016297248A1 (en) * 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
JP7633259B2 (ja) * 2019-12-24 2025-02-19 メルス ナムローゼ フェンノートシャップ ＴＧＦ－βＲＩＩ結合タンパク質

Also Published As

Publication number Publication date
JP7633259B2 (ja) 2025-02-19
AU2023200779A1 (en) 2023-03-09
CN116375869A (zh) 2023-07-04
JP2025083342A (ja) 2025-05-30
CN115038497A (zh) 2022-09-09
MX2022007919A (es) 2022-07-27
CN116199780A (zh) 2023-06-02
IL304317A (en) 2023-09-01
TW202417513A (zh) 2024-05-01
PH12022551527A1 (en) 2024-01-29
JP2023508202A (ja) 2023-03-01
BR112022012522A2 (pt) 2022-09-06
EP4269433A2 (en) 2023-11-01
KR20220117267A (ko) 2022-08-23
AU2020412201A1 (en) 2022-07-14
TW202128747A (zh) 2021-08-01
IL294181A (en) 2022-08-01
CA3165605A1 (en) 2021-07-01
KR20230145542A (ko) 2023-10-17
EP4081306A1 (en) 2022-11-02
US20250270331A1 (en) 2025-08-28
EP4269433A3 (en) 2024-05-22
WO2021133167A1 (en) 2021-07-01
AR130991A2 (es) 2025-02-05
MX2024002182A (es) 2024-05-03
JP2023076596A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
MX2021015518A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2021009793A (es) Constructos de anticuerpo para dll3 y cd3.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
AR120914A1 (es) PROTEÍNAS DE UNIÓN A TGF-b-RII
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA202190653A1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
MX2022005717A (es) Moleculas de anticuerpos anti-siglec-9.
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.
MX394911B (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
AR133025A2 (es) Constructos de anticuerpo para dll3 y cd3
MX2021002245A (es) Agentes terapeuticos peptidicos para el tratamiento de cancer y usos de los mismos.